PANews reported on March 6 that BioNexus Gene Lab Corp. (Nasdaq: BGLC), a technology company dedicated to technological innovation and healthcare, announced that its board of directors has formally approved the company's new Ethereum-focused financial strategy. This decision marks BGLC as the first Nasdaq-listed company to exclusively prioritize Ethereum as a strategic financial asset, and echoes the recent announcement that Ethereum was included in the U.S. "Cryptocurrency Strategic Reserve."

At the same time, BGLC released the Ethereum Strategic White Paper, which details the rationale behind the company's decision and the broader significance of Ethereum as a financial infrastructure asset. The white paper delves into Ethereum's institutional adoption, staking capabilities, and upcoming protocol upgrades that underpin Ethereum's long-term value and usefulness for businesses.